What's Happening?
Median Technologies has reported its financial results for 2025 and provided key business highlights for the first quarter of 2026. The company, known for its AI-powered imaging services for oncology clinical trials, achieved a record order backlog of €79.8
million as of March 2026. This growth is attributed to the company's strategic focus on expanding its iCRO business and the successful FDA clearance of its eyonis® LCS device for lung cancer screening. The company is also preparing for the commercial launch of this device in the U.S., with plans to expand its market reach through strategic partnerships.
Why It's Important?
Median Technologies' advancements highlight the growing role of AI in healthcare, particularly in cancer diagnosis and treatment. The company's financial growth and strategic initiatives underscore the increasing demand for AI-driven solutions in the medical field. The successful FDA clearance of the eyonis® LCS device marks a significant milestone, potentially transforming lung cancer screening and early diagnosis. This could lead to improved patient outcomes and reduced healthcare costs. The company's expansion into new therapeutic areas and markets also reflects the broader trend of integrating AI into various aspects of healthcare, promising enhanced efficiency and accuracy.
What's Next?
Median Technologies plans to continue its strategic expansion by securing additional distribution agreements and strengthening its U.S. commercial infrastructure. The company anticipates the first U.S. sites to be operational by Q3 2026, with revenue generation expected by the end of the year. In Europe, a decision on the CE marking for eyonis® LCS is expected in Q2 2026, which could facilitate broader adoption across European lung cancer screening programs. The company also aims to develop additional AI-driven medical devices, further solidifying its position in the early cancer diagnosis market.
